Here’s an interview with an anthropologist who studies psychedelics, and what trends she notices so far.
Read morePsilocybin's Effects on the Brain
UC Berkeley’s Groundbreaking Study on Psilocybin
This investigation represents the university’s first human trials involving a Schedule I substance, classified by the federal government as having no accepted medical use.
Psilocybin, commonly known as “shrooms” or “magic mushrooms,” can significantly distort users’ sense of time, mood, and reality, often causing hallucinations.
Read moreAre Animals Conscious?
Cluster Headaches and Psychedelics
Here’s a wonderful article on how people with cluster headaches became unexpected psychedelic pioneers.
Read moreF.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read morePsilocybin for Anorexia
This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.
The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.
Read moreMDMA Trials for PTSD Facing Setbacks?
Two articles cover this recent update.
npr: Misconduct claims may derail MDMA psychedelic treatment for PTSD
Axios: Landmark review spotlights challenge of judging psychedelic therapies
Read moreStudy: Psychedelics and the Inner Healer
Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic users.
Read moreNovel 5-MeO-DMT Formulation BPL-003
Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin).
Read morePsychological Flexibility and Psychedelics
In a new study, researchers found that psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16.
Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin.
Keep reading for the full article at Nature.com
Read more